- Home
- SCPH vs CRBU Comparison
SCPH vs CRBU Comparison
Compare SCPH & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCPH
- CRBU
- Stock Information
- Founded
- SCPH 2013
- CRBU 2011
- Country
- SCPH United States
- CRBU United States
- Employees
- SCPH N/A
- CRBU N/A
- Industry
- SCPH Biotechnology: Pharmaceutical Preparations
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- SCPH Health Care
- CRBU Health Care
- Exchange
- SCPH Nasdaq
- CRBU Nasdaq
- Market Cap
- SCPH 179.6M
- CRBU 151.2M
- IPO Year
- SCPH 2017
- CRBU 2021
- Fundamental
- Price
- SCPH $3.24
- CRBU $1.52
- Analyst Decision
- SCPH Strong Buy
- CRBU Strong Buy
- Analyst Count
- SCPH 2
- CRBU 5
- Target Price
- SCPH $15.00
- CRBU $11.80
- AVG Volume (30 Days)
- SCPH 412.0K
- CRBU 1.6M
- Earning Date
- SCPH 03-12-2025
- CRBU 03-10-2025
- Dividend Yield
- SCPH N/A
- CRBU N/A
- EPS Growth
- SCPH N/A
- CRBU N/A
- EPS
- SCPH N/A
- CRBU N/A
- Revenue
- SCPH $30,278,000.00
- CRBU $11,475,000.00
- Revenue This Year
- SCPH $172.64
- CRBU N/A
- Revenue Next Year
- SCPH $131.43
- CRBU N/A
- P/E Ratio
- SCPH N/A
- CRBU N/A
- Revenue Growth
- SCPH 303.87
- CRBU N/A
- 52 Week Low
- SCPH $3.08
- CRBU $1.50
- 52 Week High
- SCPH $6.54
- CRBU $8.33
- Technical
- Relative Strength Index (RSI)
- SCPH 40.08
- CRBU 34.82
- Support Level
- SCPH $3.27
- CRBU $1.50
- Resistance Level
- SCPH $3.59
- CRBU $1.69
- Average True Range (ATR)
- SCPH 0.20
- CRBU 0.13
- MACD
- SCPH -0.01
- CRBU -0.01
- Stochastic Oscillator
- SCPH 15.00
- CRBU 3.70
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.